Gary Raskob to Adult
This is a "connection" page, showing publications Gary Raskob has written about Adult.
Connection Strength
1.081
-
Cancer-associated venous thromboembolism: Incidence and features in a racially diverse population. J Thromb Haemost. 2022 10; 20(10):2366-2378.
Score: 0.088
-
Incidence of Venous Thromboembolism in a Racially Diverse Population of Oklahoma County, Oklahoma. Thromb Haemost. 2021 Jun; 121(6):816-825.
Score: 0.079
-
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb 15; 378(7):615-624.
Score: 0.063
-
Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 May; 3(5):e228-36.
Score: 0.056
-
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost. 2016 06 02; 115(6):1240-8.
Score: 0.056
-
Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thromb Haemost. 2016 Apr; 115(4):809-16.
Score: 0.055
-
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost. 2015 Nov 25; 114(6):1268-76.
Score: 0.054
-
Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. J Thromb Haemost. 2014 Jun; 12(6):824-30.
Score: 0.050
-
Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med. 2010 Apr; 38(4 Suppl):S502-9.
Score: 0.037
-
Exclusion of first-episode deep-vein thrombosis after-hours using D-dimer. Blood Coagul Fibrinolysis. 2007 Dec; 18(8):795-800.
Score: 0.032
-
Injury prevention and control research and training in accredited schools of public health: a CDC/ASPH assessment. Public Health Rep. 2006 May-Jun; 121(3):349-51.
Score: 0.028
-
Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings. Chest. 2004 Mar; 125(3):851-5.
Score: 0.024
-
ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003 Jul 01; 102(1):60-8.
Score: 0.023
-
Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021 08 12; 385(7):609-617.
Score: 0.020
-
Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis. Clin Appl Thromb Hemost. 2021 Jan-Dec; 27:10760296211053316.
Score: 0.020
-
Withholding treatment in patients with acute pulmonary embolism who have a high risk of bleeding and negative serial noninvasive leg tests. Am J Med. 2000 Sep; 109(4):301-6.
Score: 0.019
-
Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. Thromb Haemost. 2019 Mar; 119(3):461-466.
Score: 0.017
-
The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. Thromb Res. 2018 10; 170:75-83.
Score: 0.017
-
Idiopathic thrombocytopenic purpura: diagnosis and management. Am J Med Sci. 1998 Aug; 316(2):87-93.
Score: 0.017
-
Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2018 Jul; 118(7):1270-1278.
Score: 0.016
-
Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults. American Society of Hematology. Ann Med. 1998 Feb; 30(1):38-44.
Score: 0.016
-
Idiopathic thrombocytopenic purpura: A concise summary of the pathophysiology and diagnosis in children and adults. Semin Hematol. 1998 Jan; 35(1 Suppl 1):5-8.
Score: 0.016
-
Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2017 12; 117(12):2406-2414.
Score: 0.016
-
Clinical decisions in idiopathic thrombocytopenic purpura. Hosp Pract (1995). 1997 Sep 15; 32(9):159-60, 163-6, 169-70, passim.
Score: 0.016
-
Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 Sep; 3(9):e437-45.
Score: 0.015
-
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost. 2016 Sep 27; 116(4):747-53.
Score: 0.014
-
Aging and heparin-related bleeding. Arch Intern Med. 1996 Apr 22; 156(8):857-60.
Score: 0.014
-
Global public awareness of venous thromboembolism. J Thromb Haemost. 2015 Aug; 13(8):1365-71.
Score: 0.013
-
Cost effectiveness of diagnosis of deep vein thrombosis in symptomatic patients. Thromb Haemost. 1995 Jul; 74(1):189-96.
Score: 0.013
-
Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015 Jan 15; 372(3):232-40.
Score: 0.013
-
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29; 369(9):799-808.
Score: 0.012
-
Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 02 21; 368(8):699-708.
Score: 0.011
-
Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet. 2012 Jan 14; 379(9811):123-9.
Score: 0.010
-
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23; 363(26):2487-98.
Score: 0.010
-
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost. 2010 Dec; 104(6):1150-7.
Score: 0.010
-
The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011 Jan; 139(1):128-37.
Score: 0.009
-
Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010 Feb; 137(2):376-87.
Score: 0.009
-
Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 Aug 06; 361(6):594-604.
Score: 0.009
-
Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009 Apr; 101(4):762-9.
Score: 0.009
-
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008 Sep 15; 112(6):2242-7.
Score: 0.008
-
Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. J Thromb Haemost. 2007 Jun; 5(6):1191-4.
Score: 0.008
-
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006 Dec; 119(12):1062-72.
Score: 0.007
-
Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol. 2003 Nov; 74(3):161-9.
Score: 0.006
-
Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med. 1983 Jun; 98(6):891-9.
Score: 0.006
-
Predictive value of compression ultrasonography for deep vein thrombosis in symptomatic outpatients: clinical implications of the site of vein noncompressibility. Arch Intern Med. 2000 Feb 14; 160(3):309-13.
Score: 0.005
-
Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med. 2000 Jan 24; 160(2):229-36.
Score: 0.005
-
The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med. 1998 Jan 01; 128(1):1-7.
Score: 0.004
-
Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Arch Intern Med. 1997 Feb 10; 157(3):298-303.
Score: 0.004
-
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996 Jul 01; 88(1):3-40.
Score: 0.004
-
The low-probability lung scan. A need for change in nomenclature. Arch Intern Med. 1995 Sep 25; 155(17):1845-51.
Score: 0.003
-
A noninvasive strategy for the treatment of patients with suspected pulmonary embolism. Arch Intern Med. 1994 Feb 14; 154(3):289-97.
Score: 0.003
-
Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990 May 03; 322(18):1260-4.
Score: 0.002
-
Serial impedance plethysmography in pregnant patients with clinically suspected deep-vein thrombosis. Clinical validity of negative findings. Ann Intern Med. 1990 May 01; 112(9):663-7.
Score: 0.002
-
Clinical validity of a normal perfusion lung scan in patients with suspected pulmonary embolism. Chest. 1990 Jan; 97(1):23-6.
Score: 0.002
-
A new noninvasive management strategy for patients with suspected pulmonary embolism. Arch Intern Med. 1989 Nov; 149(11):2549-55.
Score: 0.002
-
Pulmonary embolism in outpatients with pleuritic chest pain. Arch Intern Med. 1988 Apr; 148(4):838-44.
Score: 0.002
-
Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest. 1985 Dec; 88(6):819-28.
Score: 0.002